Comparison of CE-DBT and MRI in Patients With Known Breast Lesions

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 13, 2023

Primary Completion Date

August 22, 2026

Study Completion Date

August 22, 2026

Conditions
Breast Cancer
Interventions
DRUG

Iohexol 350 Mg/mL Injectable Solution

Participants will be scanned with the digital breast tomosynthesis (DBT) system before and after the intravenous administration of iodinated contrast agent, iohexol 350mg I/mL at a dose of 1.5 mL/kg body weight. Images will be acquired of the breast of interest prior to the administration of contrast, followed by at approximately 2 minutes and 5 minutes after administration. For the purposes of this study, imaging will focus on a single breast to simplify data acquisition.

Trial Locations (1)

27599

RECRUITING

University of North Carolina at Chapel Hill, Chapel Hill

All Listed Sponsors
lead

UNC Lineberger Comprehensive Cancer Center

OTHER